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Abstract 
     Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder characterized by the 
gradual degeneration and elimination of motor neurons (MNs) and denervation of skeletal 
muscles leading to paralysis, respiratory insufficiency, and death. Some familial ALS (fALS) is 
linked to mutations in the gene encoding copper, zinc superoxide dismutase 1 (SOD1). Its mutant 
forms are believed to acquire an adverse property. However, even with extensive in vivo animal 
modeling research on mutant SOD1, the true origin and onset of disease and underlying 
therapeutically relevant mechanisms on how the mutations in SOD1 cause neurodegeneration are 
unknown. An explanation for this failure can be found in attempts to translate experimental 
results that were derived from non-human animal models to clinical research for human disease 
treatment and on conceptual restrictions that the disease is only adult in its onset.  
     To compensate this limitation, human pluripotent stem cells (hPSCs), a promising source of 
vulnerable, disease-affected differentiated cells, have opened new prospects for understanding 
human tissue and organ development, disease modeling and mechanisms, and human disease-
relevant therapeutic development and exploration. Here, we tested the hypothesis that hPSCs can 
provide novel insight into human ALS pathogenesis. Using human induced pluripotent stem cells 
(iPSCs) and the CRISPR/Cas9 genome editing system, we generated iPSCs carrying a G93A-
SOD1 missense mutation. Using this mutant iPSC line, along with a patient-derived iPSC line 
with A4V-SOD1 mutation, we interrogated their directed differentiation into spinal motor 
neurons and identified neurodevelopmental and neurodegenerative defects when compared to 
isogenic wild-type neurons. The mutant MNs accumulated misfolded and aggregated forms of 
SOD1 in cell bodies and processes, including axons. They also developed distinctive axonal 
pathologies. Mutants had axonal swellings with shorter axon length and less numbers of branch 
 iii  
 
points. Moreover, structural and molecular abnormalities in presynaptic and postsynaptic size 
and density were found in the mutants. Our findings demonstrate that genome edited iPSC using 
CRISPR/Cas9-mediated targeted gene editing and their differentiation into motor neurons 
provide important tools to study mechanisms of disease in human ALS, including proteinopathy, 
axonopathy, and synaptic pathology. This work can provide needed new insight into human cell-












Thesis Advisor: Lee J. Martin, Ph.D. 
Thesis Readers: Lee J. Martin, Ph.D. and Phil Wong, Ph.D.  










I thank my parents and brother who have been true advocates of me; 
Friends who made my life in Baltimore fruitful; 
My wife who has stood by me; 
Committee members who have given me genuine support;  









This work is supported by NIH-NINDS R01 grants NS034100 and NS052098, and NS065895.   
 v  
 
Table of Contents 
                                                                                                   Page 
Abstract............................................................................................................................................ii 
Acknowledgements.........................................................................................................................iv 
Chapter 1. Introduction.....................................................................................................................1 
Chapter 2. CRISPR/Cas9-mediated genome editing of human iPSC to generate fALS cell lines..........5 
      Introduction................................................................................................................................5 
      Materials and Methods...............................................................................................................5 
      Results......................................................................................................................................10 
Isogenic iPSC line with a SOD1-G93A missense mutation was generated by 
CRISPR/Cas9 genome editing...........................................................................................10 
CRISPR/Cas9-edited cells were validated using Sanger sequencing, ddPCR, and  
off-target analysis...............................................................................................................10 
      Discussion................................................................................................................................14 
Chapter 3. Differentiation of human iPSCs into highly pure spinal motor neuron culture...........17 
      Introduction..............................................................................................................................17 
      Materials and Methods.............................................................................................................17 
      Results......................................................................................................................................21    
Highly pure spinal motor neuron cultures were generated from iPSCs.............................21 
iPSC-derived human motor neurons show synaptic maturation........................................22  
iPSC-derived motor neurons are functionally active.........................................................22    
      Discussion................................................................................................................................24 
Chapter 4. Disease phenotypes of fALS in genome-edited iPSC-derived motor neurons............26 
      Introduction..............................................................................................................................26 
      Materials and Methods.............................................................................................................26 
      Results......................................................................................................................................28 
Increased level of misfolded and aggregated SOD1 was observed in SOD1+/G93A  
and SOD1+/A4V motor neurons under basal culture conditions..........................................28 
Mutant motor neurons showed axonal pathologies and cell body attrition.......................32 
Mutant motor neurons exhibited larger postsynaptic puncta size and more numbers  
of synapses.........................................................................................................................34 
 vi  
 
      Discussion................................................................................................................................36 





List of Tables 
Page 
Table 1. Human Induced Pluripotent Stem Cell Lines Used...........................................................8 
Table 2. List of Oligonucleotide Sequences....................................................................................9 
Table 3. Summary of Off-Target Analysis....................................................................................13 
 
 
List of Figures 
Page 
Figure 1. Establishment of SOD1+/G93A iPSC…............................................................................11 
Figure 2. Differentiation of iPSCs into spinal motor neurons using small molecules...................23 
Figure 3. Functional analysis of iPSC-derived motor neurons......................................................24 
Figure 4. SOD1 Misfolding and aggregation in motor neuron cultures........................................29 
Figure 5. Axonal pathology in SOD1+/A4V and SOD1+/G93A motor neurons..................................32 
Figure 6. Cell body attrition in SOD1+/A4V and SOD1+/G93A motor neurons..................................34 









Chapter 1. Introduction 
     Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder 
characterized by the gradual degeneration and death of motor neurons. It is a fatal paralytic 
disease that causes muscle weakness, atrophy, paralysis, and ultimately, respiratory failure (Le 
Verche & Przedborski, 2010). 
     While mostly sporadic, about 10% of all ALS cases are familial which can provide a clue to 
vulnerability of motor neurons (Boylan, 2015). Certain familial cases of ALS are known to be 
associated with mutations in the superoxide dismutase 1 (SOD1) (Rosen et al., 1993), an 
antioxidant enzyme that is localized in the cytosol and other cellular compartments including 
nucleus and mitochondria. Acting as a homodimer, SOD1 binds to copper and zinc ions to 
destroy a toxic superoxide free radical (O2
-) in the body (Petrov, Daura, & Zagrovic, 2016). 
     Despite its important physiological function, the mutant forms are thought to have crucial 
roles in the pathogenesis of the disease. It has been suggested in many studies that the mutations 
of SOD1 lead to destabilization of the protein structure and promote aggregation that are known 
to be selectively toxic to motor neurons. SOD1 knockout mice show distal axonopathy (Reaume 
et al., 1996), which may mimic early stages of ALS (Fischer et al., 2014), but they do not 
develop disease identical to ALS, suggesting toxic gain-of-function of mutant SOD1 might have 
more weight pathogenically than SOD1 loss of function in ALS (Munch & Bertolotti, 2010).  
     In order to understand how SOD1-mediated ALS initiates and propagate, researchers have 
been studying mutant SOD1 in different cell types using various models of ALS (Gurney et al., 
1994; Wong et al., 1995). Jaarsma et al. specifically directed mutant SOD1 expression in neurons 
and showed induction of motor neuron degeneration and paralysis in Thy1.2-G93A transgenic 
mice (Jaarsma, Teuling, Haasdijk, De Zeeuw, & Hoogenraad, 2008). The experiment suggests a 
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motor neuron cell autonomous mechanism of disease. Another group showed that reducing the 
level of mutant SOD1-G37R within motor neurons slowed down the hindlimb weakness and 
axonal degeneration, also suggesting cell-autonomous contribution to ALS in disease onset and 
progression (Boillee et al., 2006). Non-cell autonomous components in ALS, which can 
selectively affect motor neurons, have also been widely studied. It has been shown in 
SOD1G37R∙Olig-/- chimeric mice that mutant SOD1 in cell types other than motor neurons and 
oligodendrocytes accelerated the disease onset (Yamanaka et al., 2008). In vitro co-culture of 
embryonic stem cell- or iPS cell-derived motor neurons and primary glial cells carrying SOD1-
G93A mutation reduced motor neuron survival through toxic substance release, which 
additionally supports the role of non-motor neuronal population in ALS (Di Giorgio, Boulting, 
Bobrowicz, & Eggan, 2008). 
     Even with the extensive and intensive research on the protein and the disease over the past 
decades, little is known about the mechanisms of human SOD1 toxicity to motor neurons and 
there are no effective treatments available thus far to cure the disease (Kawamata & Manfredi, 
2010). Riluzole and Edaravone are the two FDA-approved drugs for treating ALS but they may 
only extend lifespan of patients (Cruz, 2018; Fang et al., 2018).  
     A possible explanation for this shortcoming is the use of animal models that do not 
sufficiently replicate the human disease mechanisms. Many different disease models, including 
transgenic animals of ALS, have been used to understand pathogenesis and have contributed to a 
vast body of knowledge on pathobiology. Nevertheless, the outcome obtained from these models 
has not been translated into effective medical practices using disease-modifying therapies for 
ALS patients. The core of the problem may stem from the genetic variation between human and 
animals and differences in cell signaling and cell death mechanisms. In addition, overexpression 
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of mRNA or protein in some animal models and transfected cells make the models non-
physiological, producing phenotypes that are contrary to those observed from ALS patients with 
a single copy of a mutant SOD1 gene (Ludolph et al., 2010; Morrice, Gregory-Evans, & Shaw, 
2018; Philips & Rothstein, 2015).  
     Human induced pluripotent stem cells (iPSCs) are a promising source of differentiated cells 
and have recently opened new prospects for understanding human development, disease 
modeling and mechanisms, disease target identification, and therapeutic development. In 
particular, these cells can be obtained from both healthy and patient donors, making it possible 
for researchers to investigate human diseases in a physiopathological condition under the human 
genetic background. As a result, this model could complement existing models and potentially 
expedite clinical translation. 
     Here, we hypothesized that introduction of a disease-causing mutation, G93A-SOD1, to 
human iPSCs and their differentiation into spinal motor neurons will display spontaneously 
occurring ALS phenotypes and therefore, the cell line can be a valid and reliable disease model 
to study the disease. To test the hypothesis, we utilized CRISPR/Cas9 genome editing 
technology on iPSCs and introduced a SOD1-G93A missense mutation into the genome. By 
combining genome editing with stem cell differentiation approaches, we have generated highly 
pure spinal motor neuron lines that are “isogenic” to each other. With a patient-derived iPSC 
with A4V mutation as a positive control, we identified several disease phenotypes relevant to 
ALS. Misfolded and aggregated SOD1 were seen notably in the mutant motor neurons and its 
localization was not only confined to the soma but processes including the axon. Some axonal 
pathologies, including shorter axonal length, smaller number of branch points, and axonal 
swelling as well as soma attrition were observed in the mutants when compared to the wild-type. 
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As the cells were cultured longer and became more matured, smaller postsynaptic puncta sizes 
and lower synaptic puncta density were seen. Our findings suggest that iPSC-derived motor 
neurons combined with CRISPR/Cas9 genome editing technology can provide invaluable tools 
to promote in-depth study of ALS mechanisms of disease and disease target identification, and 






Chapter 2. CRISPR/Cas9-mediated genome editing of human iPSC to 
generate fALS cell lines 
Introduction 
The advent of the CRISPR/Cas9 genome editing system in recent years has allowed us to create 
desired genetic modifications within cells and organisms with relatively improved targeting 
efficiency and precision. This system requires mainly two components; a guide RNA (gRNA) 
and a CRISPR-associated endonuclease (Cas9). With the help of the gRNA, which consists of a 
scaffold sequence needed for binding to Cas9 and a DNA targeting sequence that aims at the 
locus to be modified, the Cas9 endonuclease generates a site-specific double-stranded break in 
the genome where the genomic alteration occurs (Hsu, Lander, & Zhang, 2014; H. Li et al., 
2020). Taking advantage of this reliable system, we hypothesized that CRISPR/Cas9 genome 
editing can introduce a disease-causing mutation, G93A, at SOD1 gene locus by homology-
dependent repair (HDR). Along with a single-stranded donor oligonucleotides (ssODN), which 
contains G93A-SOD1 mutation sequence, iPSCs were transfected with Cas9-gRNA 
ribonucleoprotein (RNP) by electroporation for CRISPR/Cas9-mediated HDR to generate an 
isogenic cell line. After single clone isolation and expansion, the genome-edited cells were 
validated and also tested for off-target effects. By this way, we obtained a reliable human cell 
model which expresses the mutant SOD1 at a physiological level. 
Materials and Methods 
iPSC culture: The institutional biosafety committee (JHU registration B1011021110) approved 
the use of human cells. The protocols met all ethical and safety standards for work on human 
cells. The human iPSC lines used in this study are identified in Table 1 and were characterized 
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previously (Y. Li et al., 2015; Wen et al., 2014). They were maintained on Matrigel-coated plates 
in StemFlex Medium (Gibco) and passaged every 4–6 days using EDTA or Accutase (Thermo 
Fisher Scientific). 
Genome editing of human iPSCs by CRISPR/Cas9 system: Introduction of SOD1-G93A 
missense mutation by CRISPR/Cas9 genome editing technology was carried out using a healthy 
control iPSC line (C3-1). Prior to genome editing, alkaline phosphatase live staining (Invitrogen) 
was performed to verify pluripotency of iPSCs. Cells cultured on Matrigel (Corning) in 
StemFlex medium were pre-treated with Y-27632 ROCK inhibitor (Cellagen Technology) for 4–
5 hr and dissociated with Accutase. Cells were resuspended with Cas9 nuclease (Invitrogen), 
guide RNA, and single-stranded DNA donor (Table 2) and electroporated (voltage of 1300V, 
pulse width of 10ms, 3 pulses) using Neon Transfection System (Invitrogen). After 
electroporation, cells were plated on Matrigel-coated plates and cultured for 48 hr. Cleavage 
efficiency was determined in a portion of the cells using GeneArt Genomic Cleavage Detection 
kit (Invitrogen). Remaining cells were passaged and cultured for 48–72 hr before performing 
clonal isolation. Single cells were isolated using Accutase and cultured for approximately 10–
12 days. Each clonal cell line was collected and expanded. The genome editing of each clone was 
confirmed by DNA Sanger sequencing and digital droplet PCR. Genetic off-target effects were 
also analyzed. 
Genetic off-target analysis: Potential off-target sites were analyzed by direct DNA sequencing. 
The top seven candidates were selected based on COSMID web tool (Cradick, Qiu, Lee, Fine, & 
Bao, 2014). Genomic DNA was isolated from iPSCs using DNeasy Blood & Tissue Kit 
(Qiagen). PCR amplification around the seven sites was performed and PCR products were 
sequenced. Primers used are listed in Table 3. 
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Alkaline phosphatase staining:  An alkaline phosphatase live stain (Thermo Fisher Scientific) 
was used to identify undifferentiated, pluripotent iPSCs according to manufacturer’s instruction. 
Briefly, iPSCs were washed twice with DMEM/F12 for 2-3 min. Alkaline phosphatase live stain 
was diluted at 1:500 in DMEM/F12 and cells were incubated for 20 min at 37 ℃. Cells were 
then washed twice with DMEM/F12 for 5 min. Following the wash, cells were imaged using 
Keyence BZ-X700 fluorescence microscope. 
Digital droplet PCR: Detecting SOD1-G93A mutation in genome edited iPSCs and determining 
its copy number were done by performing digital droplet PCR (ddPCR). Reaction mix was first 
prepared by adding isolated genomic DNA, 1X ddPCR supermix, 1X target (FAM-labeled) and 
wild-type (HEX-labeled) primers/probe, MseI restriction enzyme, and H2O. This was then 
loaded into DG8 cartridge along with droplet generation oil. The cartridge was placed in the 
QX200 droplet generator (Bio-Rad) for droplet generation. After the droplet was generated, they 
were transferred into a 96-well plate and thermal cycling was proceeded to amplify the sample. 
The plate containing the amplicons in droplets was subsequently placed and run in the QX200 
Droplet Reader (Bio-Rad). Data analysis was done using the Quantasoft software (Bio-Rad) 








Table 1. Human Induced Pluripotent Stem Cell Lines Used 
iPSC lines (Clone)* Gene Mutation Age of Donor Gender 
C3-1 Control N/A 40 F 
C3-1 SOD1 G93A 40 F 
GO013 SOD1 A4V 63 F 
*C3-1 and GO013 were provided by the Song lab (University of Pennsylvania) and the Rothstein 












Table 2. List of Oligonucleotide Sequences 









































Isogenic iPSC line with a SOD1-G93A missense mutation was generated by CRISPR/Cas9 
genome editing. 
To generate an isogenic iPSC line with a SOD1-G93A missense mutation, iPSC pluripotency 
was verified by alkaline phosphatase staining (Fig. 1C) prior to generating an isogenic iPSC line 
with a SOD1-G93A missense mutation. A guide RNA that specifically targets the wild-type 
allele and a single-stranded donor oligonucleotide were designed (Table 2), and together with 
Cas9 protein, they were delivered by electroporation into the cells to mediate genome editing 
(Fig. 1A and 1B). Single clones were isolated and expanded. Each clone was then frozen for 
stock and used for validation. 
CRISPR gene edited cells were validated using Sanger sequencing, ddPCR, and off-target 
analysis. 
Heterozygous SOD1-G93A mutation was confirmed by three methods; PCR amplification of the 
targeted region followed by direct DNA sequencing, droplet digital PCR, and off-target analysis. 
Sequencing the SOD1 genomic locus showed that guanine was substituted by cytosine (GGT → 
GCT, ACC → AGC in reverse complementary strand) on one allele, resulting in the G93A 
mutation in the protein (Fig. 1D). We further detected and confirmed this heterozygous mutation 
by droplet digital PCR. Using two different fluorescent-labeled (FAM or HEX) probes that target 
either the mutant or the wild-type allele, ddPCR mutation detection assay was performed. As 
seen in the figure 1E, 1F, and 1G, the amount of wild-type template (HEX) and that of the 
mutant template (FAM) were comparable, demonstrating the G93A mutation in one allele. After 
confirming the site-specific mutation, seven potential off-target sites were examined and we 
confirmed that no off-target mutations were induced by CRISPR (Table 3).  
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Figure 1. Establishment of SOD1+/G93A iPSC. 
(A) CRISPR/Cas9 genome editing workflow. (B) Schematic representation of CRISPR/Cas9-
mediated genome editing. The PAM sequence and the mutation site are shown in red and blue, 
respectively. (C) Phase-contrast image of human iPSCs and alkaline phosphatase live staining 
showing stem cell pluripotency. Scale bar, 50 µm. (D) Chromatogram demonstrating 
CRISPR/Cas9-mediated genome editing of SOD1+/+ to SOD1+/G93A. The sequence of a reverse 
complementary strand is shown.  (E) Two-dimensional ddPCR scatter plot showing the four 
droplet clusters identified with a mutant and wild-type allele; FAM/HEX negative (grey), FAM 
positive (blue), HEX positive (green), and FAM/HEX positive (orange). (F-G) Concentrations 













Table 3. Summary of Off-Target Analysis* 




GG -- hit 
GAATCTTCAATAGACACATN






GG -- hit 
GAATCTTCAATAGACACATN






GG -- hit 
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GG -- hit 
GAATCTTCAATAGACACATN






GG -- hit 
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GG -- hit 
GAATCTTCAATAGACACATN






GG -- hit 
GAATCTTCAATAGACACATN












Generation of human iPSCs harboring G93A missense mutation using CRISPR/Cas9 genome 
editing system has provided an unprecedented tool that expresses mutant G93A-SOD1 at 
physiological level under human genetic background with minimized variation. This cell line is 
novel and particularly important since G93A mutation in ALS is one of the most common forms 
and intensively studied, especially in mice, yet it has never been introduced in iPSCs before. This 
can be a great addition to the iPSC-based ALS research along with other available iPSC lines 
with SOD1 mutations including A4V, D90A, R115G, E100G, N87S, S106L, A272C, L144FVX, 
N139K, V148G, and L144F (Amoroso et al., 2013; Bhinge, Namboori, Zhang, VanDongen, & 
Stanton, 2017; Chestkov, Vasilieva, Illarioshkin, Lagarkova, & Kiselev, 2014; Imamura et al., 
2017; Naujock et al., 2016; Richard & Maragakis, 2015; Seminary, Sison, & Ebert, 2018; L. 
Wang et al., 2017).  
     Experimental design of CRISPR/Cas9 components was critical in acquiring high efficiency in 
homology directed repair (HDR), yielding precise editing. First, the protospacer adjacent motif 
(PAM) sequence, 2-6 base pair DNA sequence of 5’-NGG-3’ where N is any nucleotide base, is 
required near the intended edit site. Without the PAM sequence, Cas9 nuclease cannot 
successfully bind and cleave the target DNA sequence. Having a PAM sequence in proximity to 
the edit site will result in double-stranded break (DSB) just a few additional bases up or 
downstream from the target locus, which in turn enhances the editing efficiency. The dose of 
ssODN was another crucial element and affects the HDR frequencies. The asymmetric, single-
stranded DNA donor with the optimal concentration of 1200 nM improved efficiency (11.1% 
knockin efficiency) when compared to the ssODN concentration of 800 nM. Previous studies 
have shown that the length of ssODN also affects the result as the use of shorter or longer 
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oligonucleotides tends to increase the incidence of errors (Liang, Potter, Kumar, Ravinder, & 
Chesnut, 2017).  
     Some shortcomings of the CRISPR/Cas9 system do exist and need improvements in order to 
make it more efficient and applicable in medical practices. As already mentioned, the system is 
dictated by the availability of the PAM sequence near the edit site. For targeted loci without 
PAM sequence nearby, DSB will not occur in close proximity to the loci, resulting in low editing 
efficiency (Liang et al., 2017). Besides, DSB induced by Cas9 nuclease could be dangerous 
because unintended genetic modifications can be made after the cut. Together with possible off-
targets, it can result in unpredicted side effects including genetic damage and extensive 
mutations throughout the genome (Kosicki, Tomberg, & Bradley, 2018). Also, the current 
system in vitro relies on the cell types that are capable of cell division, meaning that non-
dividing, postmitotic cells, such as neurons, are not feasible (Tan, Huang, & Ngeow, 2018). With 
some optimizations and refinements of the system that can overcome these drawbacks, 
CRISPR/Cas9 genome editing technique can be a more robust and powerful tool.  
     The acquisition of an iPS cell line with an SOD1 mutation, G93A, supports the needs for 
revealing naturally occurring pathology and ultimately elucidating the mechanisms of ALS for 
therapeutics. In addition, combining differentiation protocols for ALS-relevant cell types, 
including motor neurons and muscle cells, could provide better understanding of the disease. For 
example, co-culture of ALS motor neurons with skeletal muscle will form neuromuscular 
junctions (NMJs), which are one of the first sites affected in ALS, and mimic the in vivo disease 
environment in human cultures (Ionescu & Perlson, 2019). Together with cell differentiation and 
in vitro multicellular co-culture approaches, the genome-edited isogenic line can possibly 
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provide the true ALS disease phenotypes as seen in human ALS tissues and possibly distinct 







Chapter 3. Differentiation of human iPSCs into highly pure spinal motor 
neuron cultures 
Introduction 
ALS is a motor neuron disease. It is characterized by gradual deterioration and death of both 
upper and lower motor neurons with lower or spinal motor neurons being anatomically and 
pathologically affected earlier as evidenced by damage in the neuromuscular junctions 
(Moloney, de Winter, & Verhaagen, 2014; Murray, Talbot, & Gillingwater, 2010). In an effort to 
effectively understand the primary cause of the disease, we used iPSCs harboring SOD1 
mutations, including a line created by CRISPR/Cas9, and hypothesized that the iPSCs can be 
differentiated into highly pure spinal motor neurons for their interrogation in cell culture. Using 
the principles of embryogenesis and small molecule morphogens, more than 80% of the cell 
population were differentiated into mature motor neurons within 28 days. These iPSC-derived 
motor neurons were not only morphologically and immunophenotypically motor neurons but 
they were also functionally active.    
Materials and Methods 
Cell culture: iPSC cell culture is described in chapter 2. For mouse embryonic fibroblasts 
(MEFs), we used CF-1 mouse embryos at approximately 13.5 days gestation. MEFs were 
cultured in Dulbecco’s modified Eagle’s medium (DMEM, Corning) supplemented with 10% 
fetal bovine serum (FBS, Hyclone), 1% Minimum Essential Medium Non-Essential Amino 
Acids (MEM-NEAA, Gibco), and 1% GlutaMAX (Gibco). Mouse cortical astrocytes, which 
were used for patch clamp recording and to enhance attachment of motor neurons, were isolated 
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from 3 to 4 postnatal day old CD1 mouse pups as described (Schildge, Bohrer, Beck, & 
Schachtrup, 2013) and cultured in DMEM supplemented with 10% FBS.  
Differentiation of human iPSCs into motor neurons: Generation of iPSC-derived spinal motor 
neurons was done using published protocols (Calder et al., 2015; Du et al., 2015; Maury et al., 
2015) with some modifications developed in this work (Fig. 2). In brief, iPSCs were passaged 
onto MEF feeder layers in DMEM/F12 culture medium supplemented with 20% KnockOut 
Serum Replacement (Gibco), 1% MEM-NEAA, 1% GlutaMAX, 10 ng/mL bFGF (PeproTech), 
0.1 mM β-mercaptoethanol (Gibco), and 10 μM Y-27632 ROCK inhibitor. On the next day, the 
medium was changed to modified N2/B27 medium (DMEM/F12:Neurobasal [1:1], 0.5% N2, 
0.5% B27, 0.1 mM ascorbic acid, and 1% GlutaMAX) containing 3 μM CHIR-99021 (Tocris), a 
glycogen synthase kinase-3 inhibitor, along with the combination of 2 μM SB-431532 (Tocris), a 
transforming growth factor-β receptor inhibitor, and 2 μM DMH-1 (Tocris), a bone morphogenic 
protein type I receptor/activin receptor-like kinase-2 (ALK2) inhibitor. iPSCs were cultured in 
this condition for 6–7 days. The cell clusters were detached with 0.1% (w/v) collagenase IV 
(Gibco) and plated on Matrigel-coated plates in the same medium supplemented with 1 μM 
CHIR-99021, 2 μM SB-431532, 2 μM DMH-1, 0.1 μM retinoic acid (RA, Sigma), and 0.5 μM 
purmorphamine (Stemgent), a hedgehog agonist. After maintaining cell clusters for 6–7 days, 
they were collected by collagenase IV and further differentiated in ultra-low attachment plates 
(Corning) containing modified N2/B27 medium with 0.5 μM RA and 0.1 μM purmorphamine 
(PUR) and grown in suspension for another 6–7 days. Cell clusters were then singlized with 
Accutase and plated on Matrigel-coated plates or on mouse primary astrocytes for additional 
10 days with 0.5 μM RA, 0.1 μM PUR, 0.1 μM Compound E (Millipore), a Notch pathway 
inhibitor, and three neurotrophic factors (PeproTech): 10 ng/ml brain-derived neurotrophic factor 
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(BDNF); 10 ng/ml ciliary neurotrophic factor (CNTF); and 10 ng/ml insulin-like growth factor 1 
(IGF-1). We also utilized alternative cell culture conditions. For neural patterning, 10 μM SB-
431532 and 200 nM LDN-193189 (Stemgent), an ALK2/3 receptor inhibitor, was used. For 
motor neuron specification, a combination of 10 μM SB-431532 and 200 nM LDN-193189 was 
used as a substitute for 1 μM CHIR-99021, 2 μM SB-431532, and 2 μM DMH-1. Lastly, for 
motor neuron differentiation, we sometimes used 0.5 μM RA, 0.1 μM purmorphamine, 5 μM 
DAPT (Stemgent), a γ-secretase inhibitor, with BDNF, CNTF, and IGF-1. In all instances, 
neuronal cultures were treated with 50 μm 5-Fluoro-2’-deoxyuridine (Sigma) on the following 
day of plating for 24 hr to inhibit proliferation of any undifferentiated progenitor cells or 
astrocytes. All culture media in each stage were changed every 2 days. Cells in each stage were 
immunophenotyped using appropriate antibodies. 
Immunofluorescence staining: Cells on glass coverslips were fixed in 4% paraformaldehyde for 
10 min at room temperature and washed three times with PBS. Fixed cells were first 
permeabilized with 0.2% Triton X-100 in PBS for 10 min and were subsequently blocked in PBS 
with 10% donkey serum for 1 hr. Following blocking, cells were incubated overnight at 4 °C 
with primary antibodies diluted in blocking solution. The following primary antibodies were 
used: goat polyclonal anti-SOX1 (1:50, R&D systems), mouse monoclonal anti-OTX2 (1:100, 
DSHB), rabbit polyclonal anti-HOXA3 (1:100, Sigma), rabbit polyclonal anti-OLIG2 (1:500, 
Millipore), mouse monoclonal anti-NKX2.2 (1:100, DSHB), mouse monoclonal anti-ISL (1:100, 
clone 40.2D6, Developmental Studies Hybridoma Bank [DSHB]), mouse monoclonal anti-Hb9 
(1:50, clone 81.5C10, DSHB), goat polyclonal anti-choline acetyltransferase (ChAT, 1:100, 
Millipore), chicken polyclonal anti-microtubule–associated protein-2 (MAP 2, 1:5000, Novus 
Biologicals), mouse monoclonal anti-TUJ1 (1:2000, clone 5G8, Promega), rabbit polyclonal 
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anti-TUJ1 (1:3000, Covance), mouse monoclonal anti-synaptophysin (SYPH, 1:300, clone EP10, 
Invitrogen), and mouse monoclonal anti-PSD95 (1:200, clone K28/43, NeuroMab). Non-immune 
IgG isotypes were used as negative controls at concentrations identical to the primary antibodies. 
After antibody incubations, cells were rinsed in PBS, incubated with secondary antibodies 
(Alexa-Fluor-488, Alexa-Fluor-594, and Alexa-Fluor-647, Thermo Fisher Scientific) diluted at 
1:500, rinsed in PBS, and then stained with Hoechst 33258 DNA dye for nuclear visualization. 
Neuromuscular junction formation: Rat L6 myoblasts were seeded on matrigel-coated coverslips 
in a 24-well plate and grown in DMEM supplemented with 10% FBS. The medium was replaced 
by DMEM with 2% horse serum at 60-70% confluency to induce myotube differentiation. iPSC-
derived motor neurons were then added to the plate with medium replaced by modified N2/B27 
medium containing 0.5 μM RA, 0.1 μM PUR, 0.1 μM Compound E, and three neurotrophic 
factors: 10 ng/ml brain-derived neurotrophic factor (BDNF); 10 ng/ml ciliary neurotrophic factor 
(CNTF); and 10 ng/ml insulin-like growth factor 1 (IGF-1). The cells were cocultured for 
additional 7-10 days and were visualized using α-bungarotoxin (α-BTX) and ChAT staining. 
Electrophysiological characterization by whole-cell patch clamp recording: DIV 28 
differentiated motor neuron culture on round coverslips (12-mm diameter) were put into a 
submersion recording chamber on an upright microscope (Zeiss AxioExaminer, Objectives: 5x, 
0.16 NA and 40x, 1.0 NA) fitted for infrared differential interference contrast (IR-DIC). The 
recording chamber was continuously superfused (2-4 ml/min) with artificial cerebrospinal fluid 
(aCSF) composed of (in mM): 125 NaCl, 26 NaHCO3, 2.5 KCl, 1.25 NaH2PO4, 1 MgSO4, 20 
glucose, 2 CaCl2, 0.4 ascorbic acid, 2 pyruvic acid, and 4 L-(+)-lactic acid; pH 7.3, 315 mOsm, 
continuously bubbled with 95% O2/5% CO2. Neurons were visualized with a digital camera 
(Sensicam QE; Cooke). Glass recording electrodes (2-4 MΩ) were filled with an internal 
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solution containing (in mM): 2.7 KCl, 120 KMeSO4, 9 HEPES, 0.18 EGTA, 4 MgATP, 0.3 
NaGTP, 20 phosphocreatine (Na), pH 7.3, 295 mOsm. Cell electrical activities were obtained by 
using a Multiclamp 700B amplifier (Molecular Devices) and an ITC-18 (Instrutech), both 
controlled by using a customized routine written by Igor Pro (Wavemetrics). 1-sec-long 10-100 
pA currents were injected into the cells to evoke action potentials and -20 pA currents were 
injected to investigate hyperpolarizing responses of the cells. In a subset of current-step test, cells 
membranes were held at ~80 mV to see action potential initiation more clearly. All signals were 
low-pass filtered at 10 kHz and sampled at 20 kHz. 
Microscopy and image acquisition: Cells on coverslips were mounted in ProLong Gold Antifade 
Mountant (Thermo Fisher Scientific, P36930) and confocal images were taken and analyzed 
using Leica TCS SP8 microscope and LAS X software (Leica, Germany). 
Results 
Highly pure human spinal motor neuron cultures were generated from iPSCs. 
Using this genome-edited SOD1-G93A iPSC line along with its isogenic control wild-type and 
patient-derived SOD1-A4V iPSC lines, we differentiated cells into highly pure spinal motor 
neurons, as confirmed by motor neuron markers. We first promoted neural induction using iPSCs 
to generate neural progenitor cells (NPCs). From immunofluorescence staining, we showed that 
nearly all the cells after 6-7 days of differentiation were SOX1, which is a marker for NPCs. 
Also, we confirmed that those SOX1-positive cells were HOXA3 positive but OTX2 negative, 
demonstrating that the cells were of caudal fate, not rostral (Fig. 2C). Ventralization of NPCs 
were undergone for the following 6-7 days and motor neuron progenitors (MNPs) were 
identified by OLIG2. NKX2.2, which is another ventral spinal cord marker but mainly used for 
identifying interneuron progenitor, was used along with OLIG2 and showed that its expression 
22 
 
was completely repressed (Fig. 2D). The cells were further differentiated in suspension culture as 
spheroids for another 6-7 days. At 18–21 days of differentiation, greater than 80% of the cells 
were ISL1 and Hb9 positive (Fig. 2E and 2G). Approximately 80–90% of the cells were positive 
for ChAT, a mature motor neuron marker, and showed multipolar morphology at 28–31 days of 
differentiation (Fig. 2E and 2H).  
iPSC-derived human motor neurons show synaptic maturation. 
The iPSC-derived motor neurons were also positive for SYPH and PSD95, a presynaptic and a 
postsynaptic marker. With the average size of presynaptic puncta being generally larger than that 
of postsynaptic puncta, both SYPH+ presynaptic puncta and PSD95+ postsynaptic puncta became 
more prominent in sizes and numbers over time (Fig. 2F and 2I), indicating maturation of 
synapses in the motor neuron culture.    
iPSC-derived human motor neurons are functionally active. 
To determine whether the motor neurons are electrophysiologically functional to fire action 
potential, we performed whole cell patch-clamp recordings. As shown in Fig. 3B, the neurons 
fired functional action potentials in response to depolarizing current step injections, and 
displayed hyperpolarization followed by post-rebound action potential in response to negative 
current injections (Fig. 3C). We also checked whether these cells can form NMJs when co-
cultured with rat L6 myotubes. After 7-10 days of co-culture, we observed α-BTX bound to 
acetylcholine receptors, overlapped with ChAT-positive neurites, indicating the formation of 
NMJs (Fig. 3D). These data show that the motor neurons are not only having multipolar 





Figure 2. Differentiation of iPSCs into spinal motor neurons using small molecules. 
(A) Schematic diagram showing the protocol used for motor neuron differentiation from iPSCs. 
(B) Phase-contrast images of cell types in each differentiation stage. Scale bar, 200 µm and 25 
µm. (C) Immunofluorescence image of SOX1+ and OTX2- NEPs after 6 days of culture. Scale 
bar, 50 µm. (D) Immunofluorescence image of OLIG2+ MNPs on day 12. (E) Representative 
images of ISL1+, Hb9+, and ChAT+ MNs on day 28. (F) Representative images of SYPH+ and 
PSD95+ MNs on day 60. Scale bar, 20 µm. (G and H) Quantification of ISL1+, Hb9+, and ChAT+ 
MNs on (G) day 18 and (H) 28. (I) Quantification of SYPH+ and PSD95+ MNs on day 30 and 60. 









Figure 3. Functional analysis of iPSC-derived motor neurons 
(A) Whole cell patch-clamp recording on a motor neuron on day 28. Scale bar, 50 µm. (B) 
Induced high frequency action potential bursts. (C) Hyperpolarization induced rebound action 
potentials. (D) NMJ formation in co-culture with L6 rat myotubes. Scale bar, 50 µm.  
 
Discussion 
Although the emergence of iPSCs have undeniably opened new avenues for biomedical research, 
modeling diseases with iPSCs has been experiencing various technical challenges such as 
heterogeneous cell population including unwanted cell types and poorly differentiated immature 
cells, and genetic differences between individuals (Chen et al., 2014). In ALS studies, for 
example, having motor neurons and glia bearing the same ALS mutation in a dish could hinder 
researchers from knowing pathophysiology of the disease including the autonomy of cell 
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degeneration. Furthermore, even with the pure motor neurons and the same ALS mutation, the 
extent of genetic variation among different iPSC lines could also be an important factor to 
consider because it can skew the experimental results (Burrows et al., 2016; Guhr et al., 2018; 
Vigilante et al., 2019). 
     Using the principles of embryogenesis and small molecule morphogens, we have generated 
highly pure spinal motor neurons which liberated us from confounders of cell heterogeneity and 
thus, identified disease phenotypes will be in the cell type of interest, rather than in a non-motor 
neuron population. WNT-activation/dual SMAD inhibition-based method was used by adding a 
WNT agonist, CHIR-99021, and two SMAD inhibitors, SB-431532 and DMH-1, to iPSC culture 
as activating WNT signaling and inhibition of SMAD signaling have been shown to efficiently 
promote neural induction. WNT signaling has also been demonstrated to be vital in determining 
ventral spinal cord cell fates. As RA induces caudal neuronal subtypes and SHH is involved in 
ventralization in the spinal cord, exposure of RA and PUR, a SHH agonist, to NPCs resulted in 
motor neuron specification and differentiation. Inhibition of NOTCH signaling by a 𝛾-secretase 
inhibitor, compound E or DAPT, and supplementing neurotrophic factors to motor neurons 
further matured the cells. By day 28, we could obtain a very pure motor neuron population, 
between 80-90% of the total population, as confirmed by ISL1, Hb9, and ChAT. The rest of the 
non-motor neuron cell population, which includes undesired cell types and/or poorly 
differentiated cells, was prevented from further proliferation by addition of a mitotic inhibitor, 5-
Fluoro-2’-deoxyuridine (FUDR). Together with CRISPR/Cas9 genome editing technology, 
which allowed us to perform knockin of G93A-SOD1 mutation within the human genome of 
iPSCs, generation of an isogenic mutant motor neurons will become an invaluable tool for 




Chapter 4. Disease phenotypes of fALS in genome-edited iPSC-derived motor 
neurons 
Introduction 
Modeling ALS by combining human iPSC-derived motor neurons with SOD1 mutations and 
CRISPR/Cas9 genome editing is an advantageous and appropriate approach to understand 
various cellular and molecular aspects of the disease while carefully controlling genetic 
background and maintaining physiological condition. Here, we hypothesized that genome edited 
iPSC-derived motor neurons with SOD1-G93A mutation show human ALS-relevant disease 
phenotypes and therefore, can be a proper model to study the disease. A healthy control iPSC 
line (C3-1) and a patient-derived SOD1-A4V line (GO013) were also differentiated into motor 
neurons and used as an isogenic and a disease positive control, respectively. By using these 
strategies, we found that mutant motor neurons showed markedly increased misfolded and 
aggregated SOD1 in their cell bodies and processes. Axonopathy, which is defined as functional 
and structural degradations in the axon, were also observed in the mutants when compared to the 
wildtype. Furthermore, we observed some signs of synaptic dysregulations which could impact 
the degeneration and death of ALS motor neurons.  
Materials and Methods 
Extraction of misfolded and aggregated SOD1 in motor neuron cell lysates: Approximately 6 x 
106 motor neurons for each line were used. Cells were first washed with PBS and harvested by 
centrifugation for 5 min at 200 g, 4℃. RIPA buffer with protease inhibitor was added to the 
pellet and the cells were incubated for 20 min on ice.  During the incubation, probe sonication 
was performed briefly for 2-3 times to disrupt cell membranes and homogenize the samples. The 
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lysates were centrifuged for 10 min at 14,000 g, 4 ℃ and the supernatant (RIPA-soluble fraction) 
was collected. The pellet was washed with PBS and centrifuged again with the same condition. 
UREA buffer (8 M UREA, 4% CHAPS, 40 mM Tris, 0.2% BioLyte 3/10 ampholyte, 2 mM 
tributylphosphine) with protease inhibitor was then added to the pellet. After incubation for 30 
min at room temperature, the samples were centrifuged for 10 min at 14,000 g, 4 ℃ and 
supernatant (UREA-soluble fraction) was collected. 
Western blotting of RIPA- and UREA-soluble fractions: Protein concentrations were determined 
by Pierce BCA Protein Assay Kit (Thermo Fisher Scientific). 25 µg of proteins from RIPA-
soluble fractions and equivalent volumes of proteins from UREA-soluble fractions were loaded 
and separated by SDS-PAGE. Samples were transferred onto nitrocellulose membranes, washed 
with a blocking buffer, and probed with rabbit polyclonal anti-SOD1 (1:5000, abcam) overnight 
at 4 ℃. The membrane was washed three times in the blocking buffer for 5min and probed with 
secondary antibody conjugated with HRP (1:10,000, Invitrogen) for 1 hr. Bands were detected 
with Pierce ECL western blotting substrate (Thermo Fisher Scientific). 
Cell body size, axon length, and branch point measurement: Motor neuron spheroids on day 18 
were dispersed into single cells, plated on coverslips in 24 well plates, and grown for additional 
2, 4, and 6 days. Cells were fixed with 4% paraformaldehyde at each time point and 
immunostained with neuronal markers including TUJ1, MAP2, and Tau. Cell body sizes of 
motor neurons of each cell line at 4 days after plating were measured using ImageJ. For axon 
length measurement, an axon of a cell was first identified by a neurite that is Tau-positive but 
MAP2-negative. Using ImageJ, the length of the neurite was quantified. Only those neurons with 
axons that had more than twice the length of cell body were selected and measured. To count the 
number of branch points of both dendrites and axons, tracings of individual cells were first 
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performed. This was done semi-automatically by using the NeuronJ plugin of ImageJ with 
fluorescence images taken 4 days after plating.   
Quantification of synapse size and density: Motor neurons on day 60 were fixed and 
immunostained with the following antibodies; rabbit polyclonal anti-synapsin (1:500, Synaptic 
systems) and mouse monoclonal anti-PSD95 (1:200, clone K28/43, NeuroMab). Fluorescence 
images of motor neurons were taken and analyzed using ImageJ: The area of each puncta was 
measured for quantifying synapse size. Images used for analyses were thresholded with a 
constant value for each channel. For synaptic density, the number of puncta per 100 µm was 
measured using a plugin Puncta Analyzer.  
Statistical analysis: Statistical analyses were performed by using one-way analysis of variance 
using GraphPad Prism, version 8. All data are represented as mean ± SEM. Statistical 
significance was considered when p-value was less than 0.05. 
 
Results 
Increased level of misfolded and aggregated SOD1 was observed in SOD1+/G93A and 
SOD1+/A4V motor neurons under basal culture conditions. 
SOD1 with missense mutations associated with familial ALS is known to be more prone to 
misfolding and aggregation (Elam et al., 2003; Johnston, Dalton, Gurney, & Kopito, 2000; 
Shinder, Lacourse, Minotti, & Durham, 2001; J. Wang, Xu, & Borchelt, 2002). Although 
controversial, misfolded SOD1 has also been studied and described as a pathological feature 
found in sporadic ALS (Kabashi, Valdmanis, Dion, & Rouleau, 2007; Rotunno & Bosco, 2013). 
Using the pair of isogenic iPSC lines along with a patient-derived iPSC line with A4V-SOD1 
mutation, we examined the presence of misfolded and aggregated SOD1 in differentiated motor 
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neurons under basal culture condition. As shown in figure 4A and 4C, immunofluorescence 
results showed that approximately 20-25% of motor neurons with either A4V-SOD1 or G93A-
SOD1 mutation were positive for a well-characterized misfolded SOD1 antibodies, C4F6. In 
addition, some of those motor neurons with the reactivity had inclusions (Fig 4B and 4D). Motor 
neurons with wild-type SOD1 also showed a low level of reactivity and inclusions, perhaps 
representing basal endogenous misfolding of wildtype SOD1. These results were also confirmed 
by immunoblotting assays on RIPA detergent soluble and insoluble fractions obtained from the 
motor neuron culture. Compared to the wild-type SOD1 motor neuron culture, the amount of 
detergent insoluble SOD1 in the UREA soluble fractions of SOD1+/G93A and SOD1+/A4V motor 
neurons was notable (Fig. 4F and 4G). Moreover, when looking at the localization of misfolded 
SOD1, the protein was not only present in the cell body but also in the processes including 
dendrites and axons (Fig. 4H)   
 
Figure 4. SOD1 Misfolding and aggregation in motor neuron cultures. 
(A) Immunofluorescence images of motor neurons showing C4F6 immunoreactivity, an 
indicative of misfolded SOD1.  Scale bar, 20 µm. (B) Quantification of C4F6 and B8H10-
positive cells. (C) Experimental procedures of extracting RIPA-soluble and UREA-soluble 
fractions from motor neuron cultures. (D) Western blots showing SOD1 in RIPA-soluble and 
UREA-soluble fractions. GAPDH was used as a loading control. (E) Immunofluorescence image 
of motor neurons showing C4F6-positive inclusions. (F) Quantification of cells with C4F6 
inclusions. (G) Immunofluorescence images of motor neurons showing the localization of 
misfolded SOD1. Scale bar, 10µm. All data shown as means ± SEM. (B and F) n = minimum of 
266 cells per well with a total of 949 cells with SOD1+/A4V mutation, 876 cells with SOD1+/G93A 











Mutant motor neurons showed axonal pathologies and cell body attrition.  
As misfolded and aggregated SOD1 in motor neuron processes including axons were observed, 
we examined if there is any axonal pathology, which is a key feature of ALS, occurring in the 
mutant lines (Carpenter, 1968; Delisle & Carpenter, 1984; Fischer et al., 2004; Hirano et al., 
1984). In order for motor neurons to build a neuronal network and communicate with each other, 
they need to elongate the axon and multiple dendrites. Aberrant elongation and branching of 
processes and axonal truncations could result in neurodegeneration, leading to cell death (Delisle 
& Carpenter, 1984; Fischer & Glass, 2007). Therefore, we measured axonal length 2, 4, and 6 
days after plating individual motor neurons on day 18 and compared the mutants to the wild-
type. Two days postplating, motor neurons did not present any difference in axonal length. 
However, the axonal length in the mutants were significantly shorter on 4d and 6d postplating 
(Fig. 5A and 5B). Moreover, defects in axonal branching were observed. Motor neurons with 
A4V-SOD1 and G93A-SOD1 mutations had less number of axonal branch points when 
compared to the wild-type (Fig. 5C and 5D). Another pathological feature, which precedes 
neuronal apoptosis, we found was axonal swelling (Delisle & Carpenter, 1984). SOD1 mutant 
motor neurons displayed focal enlargement in their axons with a beaded or fragmented 
morphology (Fig. 5E). In addition to axonal pathology, cell body attrition was observed. Motor 
neurons carrying the mutations showed 20-25% reduction in soma size when compared to the 
wild-type (Fig. 6F and 6G).  
 
Figure 5. Axonal pathology in SOD1+/A4V and SOD1+/G93A motor neurons.  
(A) Representative images of motor neurons showing different axonal lengths. Scale bar, 20 µm. 
(B) Quantification of average axonal length. n = minimum of 16 cells per well with a total of 644 
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cells with SOD1+/A4V mutation, 523 cells with SOD1+/G93A mutation, and 569 cells with SOD1+/+ 
from 4 wells for each time point. (C) Representative images of neurite tracing. Numbers in red 
indicate axonal branch points in each line. (D) Quantification of dendritic and axonal branch 
points. n = minimum of 17 cells per well with a total of 258 cells with SOD1+/A4V mutation, 186 
cells with SOD1+/G93A mutation, and 176 cells with SOD1+/+ from 4 wells each. All data shown 





Figure 6. Cell body attrition in SOD1+/A4V and SOD1+/G93A motor neurons.  
(A) Immunofluorescence images of TUJ1+ motor neurons showing different soma sizes. Scale 
bar, 10 µm. (B) Quantification of soma size. n = minimum of 25 cells per well with a total of 315 
cells with SOD1+/A4V mutation, 206 cells with SOD1+/G93A mutation, and 266 cells with SOD1+/+ 
from 4 wells each. All data shown as mean ± SEM. **P < 0.01. 
 
Mutant motor neurons exhibited larger postsynaptic puncta size and more numbers of 
synapses.  
Synaptic dysregulation has been studied as an early pathological event contributing to motor 
deficits in ALS. Consequently, along with the distal axon, synapse has been receiving great 
attention as a promising target for the disease (Cantor et al., 2018; Casas, Manzano, Vaz, Osta, & 
Brites, 2016; Murray et al., 2010; van Zundert, Izaurieta, Fritz, & Alvarez, 2012). We looked for 
synaptopathy in the mutant iPSC-derived motor neurons by performing immunofluorescence 
staining (Fig. 7A) and observed some interesting results regarding synapse size and density, both 
of which are known to be highly associated with the disease progression (Sasaki & Maruyama, 
1994; Shiihashi et al., 2017; Starr & Sattler, 2018). When measuring the size of presynaptic 
puncta immunolabeled by synapsin, the results were not consistent between the two mutants; the 
average puncta size of SOD1+/A4V motor neurons was smaller than the wild-type whereas that of 
SOD1+/G93A motor neurons was larger (Fig. 7B). For the size of postsynaptic puncta labeled by 
PSD95, however, both SOD1+/A4V and SOD1+/G93A motor neurons showed significantly larger 
35 
 
puncta size than the wild-type (Fig. 7C). The synaptic puncta density (number of puncta per 
100µm), was also quantified. Although statistically not significant in general, the pre- and 
postsynaptic puncta densities were relatively higher in both mutants compared to the control 
wild-type (Fig. 7D and 7E). We also carefully examined the density of synapses, sites at which 
both synapsin and PSD95 are colocalized. More numbers of SYN+PSD95+ puncta per 100 µm 
were found in the mutants and the difference was statistically significant (Fig. 7F). 
 
Figure 7. Synaptic dysregulation in SOD1+/A4V and SOD1+/G93A motor neurons.  
(A) Immunofluorescence images of SYN+ and PSD95+ motor neurons showing pre- and 
postsynaptic puncta. Scale bar, 10 µm. (B-C) Quantification of (B) SYN+ and (C) PSD95+ 
puncta sizes. (D-F) Quantification of (D) SYN+, (E) PSD95+, and (F) SYN+PSD95+ puncta 







We have identified ALS-relevant disease phenotypes with genome-edited iPSC-derived motor 
neurons with G93A-SOD1 and the results were prominent when compared to its isogenic 
wildtype control and similar to a positive control having A4V-SOD1 mutation. We first 
examined the possible presence of misfolded and aggregated SOD1 in motor neurons, which is a 
pathological hallmark of ALS (Pare et al., 2018). To demonstrate whether the mutant motor 
neurons produce misfolded SOD1, we used a well-characterized antibody raised against 
recombinant apo G93A-SOD1, clone C4F6, and stained motor neurons (Urushitani, Ezzi, & 
Julien, 2007). This antibody has been shown to recognize misfolded forms of mutant human 
SOD1 proteins including G93A-, A4V-, and the wildtype SOD1 (Atlasi et al., 2018; Pare et al., 
2018; Pickles et al., 2016; Rotunno et al., 2014; Xu et al., 2015). As seen in Fig. 4A, 4B, and 4H, 
20-30% of mutant motor neurons showed immunoreactivity to the antibody with 10% having 
SOD1 inclusions. Wildtype motor neurons, although the amount of misfolded, insoluble form 
was significantly less than the mutants (Fig. 4E, 4F, and 4G), did show some positive signals 
with the antibody (Fig. 4C and 4D), supporting the hypothesis proposed by previous studies that 
familial ALS and sporadic ALS share some common pathways and mechanisms (Pare et al., 
2018). More interestingly, these misfolded and aggregated SOD1 proteins were localized not 
only in soma but also in the processes such as dendrites and axons (Fig. 4H). This result led us to 
investigate axonopathy that could be present in the motor neurons.  
     We first compared the axonal outgrowth of motor neurons and found pathology in the 
mutants. When measuring the length of the axon, identified as TAU-positive but MAP2-negative 
neurite, we showed a reduction of the axonal lengths by 20-30% in G93A-SOD1 and A4V-
SOD1 motor neurons 4d and 6d after plating. The number of branch points in the axons of the 
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mutants also decreased by similar extent (Fig. 5C and 5D). Moreover, bead-like swellings along 
the axons of the motor neurons with SOD1 mutations were seen (Fig. 5E).  
     These misfolded, aggregated SOD1 and some axonal pathologies that we observed in the 
mutants are meaningful as they might be related to the deficits in intracellular trafficking, which 
are one of the pathological events in ALS. Previous studies have suggested that misfolded SOD1 
disrupts ER-to-Golgi trafficking driven by COPII vesicles (Burk & Pasterkamp, 2019). Also, it 
has been shown that the mutant SOD1 inhibits kinesin- and dynein-mediated axonal transport 
(Huai & Zhang, 2019). As axonal transport is an essential cellular process responsible for the 
movement of molecular cargos including lipids, mitochondria, proteins, and cellular organelles 
in neurons (Burk & Pasterkamp, 2019), its defect has been suggested as the pathogenesis of the 
disease. The impairment of the transport system has been demonstrated to increase stalling of 
cellular cargos along the axon, resulting in axonal swelling (Fassier et al., 2013).  
     The aberrant axonal branching shown in this study is another important ALS pathology that 
may have disadvantage in neuronal network formation and signal transmission (Suzuki, 
Akiyama, Warita, & Aoki, 2020). Shorter axonal length and poor branching in the mutants could 
prevent or minimize neurons from extending multiple branches and arborizing at specific targets 
(Kalil & Dent, 2014). Motor neurons, in particular, elongate their terminal arbors to muscle 
fibers and form neuromuscular junctions (NMJs) for muscle contraction. As dismantling of 
NMJs is known to play a critical role in the onset of ALS (Cappello & Francolini, 2017), 
rescuing these disease phenotypes in the mutant motor neurons would be worthwhile. 
     Dysregulation of synapses has long been thought to play a role in many neurodegenerative 
diseases including ALS from a number of different studies. Here, we compared 60d-old, mature 
motor neurons and found some distinctive patterns in the mutants regarding synapses. The first 
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notable observation that the mutant motor neurons showed larger postsynaptic puncta size 
demonstrated by postsynapse staining with a PSD95 antibody was unexpected and also 
surprising. PSD95 is a major member of the membrane-associated guanylate kinase family and 
known for regulating glutamate receptors in the synapse. More importantly, the size and intensity 
of PSD95 puncta have been shown to correlate with synaptic development and maturity of 
excitatory synapses (El-Husseini, Schnell, Chetkovich, Nicoll, & Bredt, 2000). In iPSC-derived 
motor neurons from C9ORF72 ALS/FTD patients, cell surface levels of NMDA receptor NR1 
and the AMPA receptor GluR1 were increased and these glutamate receptors were accumulated 
at postsynaptic densities (PSD, defined as protein dense area in the postsynaptic compartment) 
(Shi et al., 2018). Overexpression of TDP-43A315T in mouse cortical neurons also showed 
elevated levels of GluR1 (Jiang et al., 2019).  
     We have also found that SYN+PSD95+synaptic puncta density was higher in the mutants. This 
corresponds to the results acquired by Fogarty et al. in which excitatory synaptic inputs and 
dendritic spine densities were increased in presymptomatic TDP-43Q331K mice, proposing 
excitatory neurotransmission as a pathophysiology of ALS, consistent with the concept of 
excitotoxicity (Fogarty et al., 2016). One of FDA drugs for treating ALS, riluzole, purportedly 
acts by blocking excitotoxicity, though no disease-modifying effects are seen. Relevant studies 
on iPSC-derived MNs with SOD1 mutations have also been done. Although a contradicting 
result, hypoexcitability of mutant iPSC-derived MNs with SOD1-D90A and SOD1-R115G 
mutations, exists (Naujock et al., 2016) (Naujock et al., 2016), Wainger et al. demonstrated 
intrinsic hyperexcitability of iPSC-derived MNs with SOD1-A4V mutation and showed reduced 
delayed-rectifier potassium currents as a driver (Wainger et al., 2014), which supports the idea of 
excitotoxicity as a mechanism of the disease (Vasques, Mendez-Otero, & Gubert, 2020). 
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Combining these previous findings, our results on synaptic dysregulation suggest that mutant 
SOD1 motor neurons exhibit more advanced maturation of synapses, with abnormal 
development of postsynapses playing a crucial role, and this could be linked to an earlier cellular 





Chapter 5. Conclusions 
     This study demonstrated that an iPSC line harboring a heterozygous G93A-SOD1 mutation, 
which was generated by CRISPR/Cas9 genome editing system, was differentiated into highly 
pure spinal motor neurons and exhibited ALS-relevant disease phenotypes.  
     Much studies have been done using genome editing systems on iPSCs but they are mostly 
focused on genetic correction of a mutation to the wildtype. Observation of rescued phenotypes 
after genetic correction is worthwhile for determining the possible clinical application of genome 
editing, including CRISPR/Cas9 system, to humans. However, generating an iPSC line with a 
disease-causing mutation from its endogenous wildtype gene and confirming the disease-related 
phenotypes is another way of validating the genome editing system and could be a valuable 
approach to study the disease mechanism. In particular, an iPSC expressing G93A-SOD1 
mutation has never been generated before. This is especially important as the G93A variant is 
one of the highly studied mutations in ALS and known to have relatively rapid disease 
progression. Thus, our novel cell line is very suitable for ALS research (Pansarasa et al., 2018). 
Also, it can be a good comparison to the G93A-SOD1 Transgenic (Tg) mouse or rat, a most 
widely used and characterized rodent model of ALS. Extensive research on ALS pathogenesis 
using the Tg-mice has been done for decades but translating the findings from this model to 
clinical practices has not been successful in general. A possible explanation for this failure is the 
high copy numbers of human G93A-SOD1 expressed in non-human animals. From this aspect, 
our iPS cell model, which expresses G93A-SOD1 mutation at physiological level under human 
genetic background, is a new and alternative tool which can compensate for the current 
limitations of Tg-mice. 
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     Our findings with the iPSC-derived motor neurons have several meaningful implications. 
First, we biochemically extracted detergent-insoluble mutant SOD1 from iPSC-derived motor 
neurons and showed its presence under basal culture condition (Fig. 4E, 4F, and 4G). This result 
contradicts a previous study that insoluble SOD1 protein was only found when treating iPSC-
derived motor neurons with MG132 proteasome inhibitor (Kiskinis et al., 2014) and supports the 
idea that misfolding and aggregation of SOD1 is a spontaneous pathological hallmark and a 
possible driver of the disease intrinsic to proteasome dysfunction.  
     Another ALS-relevant disease phenotype that we found was axonal pathology. We found 
several spontaneously occurring disease indicators related to axonopathy. For human iPSC-
derived G93A-SOD1 harboring motor neurons, these findings are novel and robust. Mutant 
motor neurons exhibited shorter axonal length, less number of branch points, and axonal 
swelling. A related trend of having axonal defects, including the number of primary branches, 
growth cone area, and neurite length, in iPSC-derived neurons have been demonstrated in 
previous studies on ALS with a different mutation (Groen et al., 2013) or on different motor 
neuron diseases such as hereditary spastic paraplegias (Havlicek et al., 2014; Rehbach et al., 
2019). On the other hand, a recent study on SOD1-G93A Tg mouse model showed enhanced 
axonal outgrowth and neurite branching in adult motor neurons, as opposed to our data (Osking 
et al., 2019). However, culture of adult mammalian spinal cord motor neurons is technically 
challenging and survival and growth is very limited. The discrepancy may be due to variation 
between the species but may also stem from different stages of disease progression or functional 
age and viability of cells. Although comparison between the maturity of iPSC-derived spinal 
motor neurons in cell culture and that of spinal motor neurons in vivo have not been clearly 
addressed, there is a study suggesting that iPSC-derived motor neurons in vitro resemble fetal 
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spinal tissues more than adult spinal tissues when their transcriptomes were analyzed (Ho et al., 
2016). However, these results might be highly dependent on densities of the cells in culture and 
their electrophysiological activities. One might argue that maturation and aging of iPSC-derived 
motor neurons is needed for better modeling. However, this could be advantageous as the disease 
phenotypes observed from iPSC-derived motor neurons may reflect early pathology of the 
disease hence, the results may be better suitable for disease-modifying clinical application.  
     Excitotoxicity is an enduring proposed mechanism of ALS pathogenesis (Rothstein, 1995; 
Van Damme, Dewil, Robberecht, & Van Den Bosch, 2005). The larger postsynaptic puncta size 
and higher synaptic density in the mutant motor neurons could imply enhanced excitatory 
neurotransmission which could potentially lead to excitotoxicity of neurons. It could also be a 
compensatory response of the mutant motor neurons having aberrant axonal elongation and 
branching, and the potential need to augmented excitatory drive. Excitotoxicity is mediated by 
glutamate receptors and their biology is extraordinarily complex (Dingledine, Borges, Bowie, & 
Traynelis, 1999). Many species differences are also being discovered in the function and 
diversity of glutamate receptors (Mayer, 2020). Further investigation is needed to find the 
linkage between the synaptic dysregulations and excitotoxicity in human motor neurons.  
     Another notable observation was presynaptic puncta size discrepancy between the two 
mutants; presynaptic puncta size of A4V-SOD1 motor neurons was smaller than the wildtype 
and that of G93A-SOD1 motor neurons was larger, with the size of A4V-SOD1 being close to 
40% smaller than G93A-SOD1 motor neurons. This suggests that even though the two mutations 
are within the SOD1 gene locus, different mutations could have discrete mechanisms or at least 
display different magnitudes or severities in the development of the disease. A variant of this 
idea has been articulated before because the same gene mutation can cause different disease 
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phenotypes (Kammenga, 2017) and the general interpretation is that the genetic background and 
presence of genetic modifiers are playing a significant role in disease development.  
      In conclusion, the identification of ALS-relevant disease phenotypes in genome-edited, 
iPSC-derived motor neurons with G93A heterozygous mutation reveals that this cell line was 
verified as an unprecedented human disease model and can be used to study underlying 
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